Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Spain, and Estonia for its novel anti-microbial agent MRX-4 combined with contezolid (MRX-I) as a sequential treatment for diabetic foot infection.
Drug Overview and Development
Both drugs are in-house developed new-generation oxazolidinone antibiotics. Contezolid was approved in China in June 2021 to treat complex skin and soft tissue infections. MRX-4, meanwhile, is contezolid acefosamil, the pro-drug version of contezolid (MRX-1), a potent oxazolidinone antibiotic against Gram-positive pathogens.-Fineline Info & Tech